Cargando…

Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma

Background: The SPOTLIGHT trial demonstrated that zolbetuximab plus mFOLFOX6 (ZOL-FO) as a first-line regimen compared with placebo plus mFOLFOX6 (PLB-FO) conferred clinical benefits to patients with CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Yufan, You, Maojin, Wu, Qundan, Chen, Ruijia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500349/ https://www.ncbi.nlm.nih.gov/pubmed/37719841 http://dx.doi.org/10.3389/fphar.2023.1238009

Ejemplares similares

Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma
por: Shitara, Kohei, et al.
Publicado: (2022)

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
por: Shah, Manish A., et al.
Publicado: (2023)

Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma
por: Lordick, Florian, et al.
Publicado: (2021)

Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma
por: Wang, Xi, et al.
Publicado: (2022)

ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma
por: Klempner, Samuel J., et al.
Publicado: (2023)

A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma
por: Sun, Weijing, et al.
Publicado: (2023)

Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
por: Takahashi, Takao, et al.
Publicado: (2022)

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
por: Bendell, Johanna C., et al.
Publicado: (2019)

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013)

Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer
por: Zhao, Shen, et al.
Publicado: (2022)

Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma
por: Shamseddine, Ali, et al.
Publicado: (2020)

Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
por: Oki, Eiji, et al.
Publicado: (2019)

mFOLFOX6 Chemotherapy after Resection of Anal Canal Mucinous Adenocarcinoma
por: Matsunaga, Mototsugu, et al.
Publicado: (2016)

Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab
por: Matsunaga, Mototsugu, et al.
Publicado: (2016)

CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
por: Gao, Jing, et al.
Publicado: (2023)

Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma
por: Shamseddine, Ali, et al.
Publicado: (2020)

CLDN18.2-targeted molecular imaging and precision therapy of gastrointestinal tumors
por: Chen, Yan, et al.
Publicado: (2023)

Clinical Significance of CLDN18.2 Expression in Metastatic Diffuse-Type Gastric Cancer
por: Kim, Seo Ree, et al.
Publicado: (2020)

Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indications
por: Chen, Jinxia, et al.
Publicado: (2023)

CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer
por: Wang, Canming, et al.
Publicado: (2023)

A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy
por: Liang, Jie, et al.
Publicado: (2021)

A complete response to mFOLFOX6 and panitumumab chemotherapy in advanced stage rectal adenocarcinoma: a case report
por: Sonoda, Hiromichi, et al.
Publicado: (2014)

Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer
por: Zhu, Guoyun, et al.
Publicado: (2019)

Pathological complete response to mFOLFOX6 plus cetuximab therapy for unresectable colon cancer with multiple paraaortic lymph node metastases
por: Suetsugu, Tomonari, et al.
Publicado: (2018)

Acute Myocardial Infarction Due to Coronary Artery Embolism during Chemotherapy with mFOLFOX-6 Plus Bevacizumab for Metastatic Colon Cancer
por: Aoshima, Hiroyuki, et al.
Publicado: (2022)

Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas
por: Klempner, S.J., et al.
Publicado: (2023)

Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas
por: Pellino, Antonio, et al.
Publicado: (2021)

The Comparison of mDCF and mFOLFOX-6 as First-Line Treatment in Metastatic Gastric Cancer
por: Acikgoz, Yusuf, et al.
Publicado: (2021)

The IL1β-HER2-CLDN18/CLDN4 axis mediates lung barrier damage in ARDS
por: Ma, Xinhua, et al.
Publicado: (2020)

Characterization of zolbetuximab in pancreatic cancer models
por: Türeci, Ӧzlem, et al.
Publicado: (2018)

Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer
por: Jia, Keren, et al.
Publicado: (2022)

Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors
por: Chen, Yan, et al.
Publicado: (2023)

Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients
por: Sugimoto, Shinichi, et al.
Publicado: (2009)

Disturbance of consciousness due to hyperammonemia and lactic acidosis during mFOLFOX6 regimen: Case report
por: Fukuda, Masafumi, et al.
Publicado: (2020)

A Phase II Clinical Study of mFOLFOX6 Plus Bevacizumab as First-line Therapy for Japanese Advanced/Recurrent Colorectal Cancer Patients
por: Nishina, Tomohiro, et al.
Publicado: (2013)

Long-term stable disease with mFOLFOX6 chemotherapy plus cetuximab for bone marrow metastasis from rectal cancer: A case report
por: Fan, Xiumei, et al.
Publicado: (2023)

Author Correction: Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer
por: Zhu, Guoyun, et al.
Publicado: (2019)

Comment on: “Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors”
por: Li, Cuicui, et al.
Publicado: (2023)

Correction: Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer
por: Jia, Keren, et al.
Publicado: (2023)

Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C(3)) study
por: Nagasaka, Takeshi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_43u6jcflbcl2f3dk16oue687u5